Scarica l'app Stockscreener
37.55
2.18%
0.80
Pre-mercato:
37.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$36.75
Aprire:
$37.17
Volume 24 ore:
496.53K
Relative Volume:
0.63
Capitalizzazione di mercato:
$2.16B
Reddito:
$772.53M
Utile/perdita netta:
$180.90M
Rapporto P/E:
12.10
EPS:
3.1024
Flusso di cassa netto:
$258.73M
1 W Prestazione:
+0.35%
1M Prestazione:
-5.72%
6M Prestazione:
+16.47%
1 anno Prestazione:
+6.74%
Intervallo 1D:
$37.05
$38.11
Intervallo di 1 settimana:
$35.42
$38.11
Portata 52W:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
37.55 | 2.12B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Harmony Biosciences Holdings (HRMY) Stock Analysis: A Revenue Growth Powerhouse with 25.66% Upside Potential - DirectorsTalk Interviews
Top 5 US Stocks To Buy In January 2026 - Investing.com
(HRMY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
26,279 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Paradiem LLC - MarketBeat
Exchange Traded Concepts LLC Buys 32,923 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastContrarian Investment Ideas & Big Gains Small Trading - earlytimes.in
Quarterly Trades: What is the fair value of Harmony Biosciences Holdings Inc stock nowTrade Risk Summary & Daily Oversold Stock Bounce Ideas - moha.gov.vn
Why Harmony Biosciences Holdings Inc. stock is popular among millennials2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Price-Driven Insight from (HRMY) for Rule-Based Strategy - Stock Traders Daily
Can Harmony Biosciences Holdings Inc. stock maintain operating marginsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Harmony’s Epilepsy Drug Cuts Seizures in Half in Key Late-Stage Study - MyChesCo
Will Harmony Biosciences Holdings Inc. stock outperform growth indexesMarket Risk Report & Community Verified Trade Alerts - DonanımHaber
Why Harmony Biosciences Holdings Inc. stock attracts high net worth investors2025 Price Targets & Daily Entry Point Alerts - DonanımHaber
Why Harmony Biosciences Holdings Inc. stock appeals to dividend seekersJuly 2025 Outlook & Verified Chart Pattern Trade Signals - DonanımHaber
Will Harmony Biosciences Holdings Inc. stock outperform value stocksBull Run & Safe Entry Momentum Tips - Улправда
Downgrade Watch: Is Harmony Biosciences Holdings Inc. stock positioned well for digital economyWatch List & Stepwise Swing Trade Plans - DonanımHaber
Dow Update: Will Harmony Biosciences Holdings Inc. stock outperform Dow Jones indexWeekly Trend Summary & Long-Term Growth Plans - Улправда
How sustainable is Harmony Biosciences Holdings Inc. stock dividend payoutEarnings Growth Summary & Trade Opportunity Analysis Reports - Улправда
Is Harmony Biosciences Holdings Inc. stock resilient to inflation2025 Winners & Losers & Community Consensus Trade Signals - Улправда
Harmony Biosciences (NASDAQ:HRMY) Trading Down 3.9% After Insider Selling - MarketBeat
Street Watch: Will Harmony Biosciences Holdings Inc. stock outperform international peersJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Aug Wrap: How sustainable is Harmony Biosciences Holdings Inc. stock dividend payoutJuly 2025 Breakouts & Technical Entry and Exit Alerts - Улправда
Will Harmony Biosciences Holdings Inc. stock outperform Dow Jones index2026 world cup usa national team qualification young talents low block defense match prediction insights - Улправда
Harmony Biosciences (NASDAQ:HRMY) CEO Sells $1,040,172.63 in Stock - MarketBeat
Harmony Biosciences Holdings CEO Sells All Directly Owned Common Stock - TradingView — Track All Markets
Harmony Biosciences CEO reports option exercise and share sale | HRMY SEC FilingForm 4 - Stock Titan
Harmony Biosciences (HRMY): Evaluating Valuation After New EPX-100 Phase 3 Data and Beacon Biosignals Collaboration - Sahm
Harmony Biosciences partners with Beacon for EEG data in sleep trials - Investing.com Nigeria
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG - Investing News Network
Harmony Biosciences partners with Beacon for EEG data in sleep trials By Investing.com - Investing.com South Africa
Beacon Biosignals announces partnership with Harmony Biosciences - marketscreener.com
Nomura Holdings Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN
Growth Value: Will Harmony Biosciences Holdings Inc stock pay special dividendsTrade Ideas & Real-Time Buy Zone Alerts - moha.gov.vn
Federated Hermes Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Shows Niche Pharma Momentum Nasdaq Today - Kalkine Media
Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
What analysts say about Harmony Biosciences Holdings Inc stockAutomated Trading Signals & Missed Nvidia? Don’t Miss This One - earlytimes.in
Harmony Biosciences CFO Kapadia Sandip Sells 20,000 Shares - TradingView — Track All Markets
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MSN
Harmony Biosciences (HRMY) Shares Promising Phase 3 Trial Results for EPX-100 - GuruFocus
Harmony Biosciences reports positive data for Dravet syndrome drug By Investing.com - Investing.com South Africa
Harmony Biosciences shows seizure reduction in dravet syndrome trial - StreetInsider
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
Marshall Wace LLP Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results - MyChesCo
Arrowstreet Capital Limited Partnership Grows Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):